Abbott Laboratories beats second quarter 2026 estimates and raises full-year guidance on strong Medical Devices and Diagnostics growth.

Abbott Laboratories reported second-quarter sales of $12.59 billion and adjusted EPS of $1.31, exceeding analyst expectations. Results were driven by strong performance in Medical Devices and the contribution from the recent Exact Sciences acquisition, leading the company to raise its full-year adjusted EPS forecast.

Key Highlights

• Abbott raised its full-year 2026 adjusted diluted EPS guidance to a range of $5.45 to $5.60, up from the previous range of $5.38 to $5.58.
• The Medical Devices segment delivered strong results, with sales increasing 9.0 percent on a reported basis, led by low-teens growth in Electrophysiology.
• Diagnostics segment sales surged 42.3 percent on a reported basis, primarily driven by the inclusion of the newly acquired Cancer Diagnostics business (Exact Sciences).
• The Nutrition segment remained a weak spot, with worldwide sales declining 3.1 percent on a reported basis compared to the prior year.